Oncocyte Strengthens Leadership Team with CFO Appointment

This month, precision diagnostics company, Oncocyte Corporation (Nasdaq: OCX) further strengthened its leadership team with the appointment of leading finance executive Andrea James as Chief Financial Officer.

Oncocyte has reached an exciting point in its evolution as a company, and is expecting to meet a number of critical commercial and regulatory milestones during 2024 and into 2025. The company is currently focused on the commercial launch of its VitaGraft™ Kidney diagnostic test, and the commercialization of its research use only (RUO) GraftAssure™ assay, which is now shipping to academic transplant centers in the US, the EU, and Asia.

Commenting on the appointment, Oncocyte CEO, Josh Riggs, said in a statement, “We are thrilled to welcome Andrea as we approach the inflection point of commercial launch. She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team.”

Mr. Riggs stated that he expects 2024 and 2025 to be transformative years for the company as it works to establish its diagnostic tests as the research tool of choice for the transplant community alongside its marketing partner, Bio-Rad Laboratories. Oncocyte announced that it had entered an important commercialization partnership with Bio-Rad, a global leader in the life science research and clinical diagnostic markets, which included a $3.5 million upfront investment.

Ms. James brings a wealth of experience to the role, and her leadership and strategic insights are eagerly anticipated by investors. Prior to joining Oncocyte, she served as Chief Communications Officer and head of investor relations at Axon Enterprise, Inc. (Nasdaq: AXON), playing an integral role in the company’s growth from $1 billion in market capitalization to a value of more than $20 billion. She led Axon’s repositioning as a top-tier technology company with the investment community and established Axon’s corporate strategy function, overseeing capital stewardship, mergers and acquisitions, strategic partnerships and investments. Her work was instrumental in supporting more than $550 million in equity capital offerings.

“Oncocyte is a disruptive innovator in the field of molecular diagnostics that is on track for category leadership. The company enjoys a top-notch management team with extensive experience in this space,” Ms. James said in a company announcement. “I am delighted to join and look forward to helping to scale the company into a much larger, highly profitable enterprise over time, while also ensuring that the capital markets understand our exciting runway and global market opportunity.”

Ms. James holds a Bachelor of Science, summa cum laude, in Computer Information Systems from American University. She also holds a Master of Science in Journalism from Northwestern University, graduating with Kappa Tau Alpha honors.

About Oncocyte

Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:

VitaGraft Kidney™ – https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ – https://oncocyte.com/vitagraft-liver/
GraftAssure™ – https://oncocyte.com/graftassure/
DetermaIO™ – https://oncocyte.com/determa-io/
DetermaCNI™ – https://oncocyte.com/determa-cni/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

Oncocyte Strengthens Leadership Team with CFO Appointment

Catie Corcoran

Biotech Editor